A new startup has launched out of Cambridge-based venture capital firm Flagship Pioneering with what it hopes could be an industry-changing formula: mix cells and artificial intelligence to create treatments for any and all diseases. Cellarity was created by Flagship CEO Noubar Afeyan and two employees working who were then working at another of the venture capital firm’s startups: Ring Therapeutics, which is still…
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has entered into a strategic commercial supply agreement with CarThera® for the use of Lantheus’ microbubbles in combination with SonoCloud®, a proprietary implantable device in development…
Drug giant Merck & Co. announced Monday that it will spend billions to buy a 26-year old biotech company that’s struggled to bring a cancer drug to market. Merck (NYSE: MRK) will spend approximately $2.7 billion to acquire Burlington-based ArQule Inc. (Nasdaq: ARQL). The biotech’s drug that’s furthest along in clinical trials is in the mid-stage tests against relapsed or refractory chronic…
Irvine, California-based Healthpeak Properties has acquired the Alewife Research Center in West Cambridge from The Davis Cos. for $332.5 million. The ARC is a 224,305-square-foot Class A lab property and 331-space parking garage located at 35 CambridgePark Drive, which The Davis Cos. completed development last November. The speculative property has since been fully leased to five biopharmaceutical/biotech companies: Eisai, a Japanese pharmaceutical firm that…
“Proteins are the workers in the cell, and it’s important to know their shape,” says Chris Sander, PhD, director of Dana-Farber’s cBio Center in the Department of Data Sciences. Sander and his colleagues have now demonstrated a powerful “experimental evolution” method to discover details of protein shape and function, and the method may find uses across a very broad spectrum of…
For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests. The study will be presented today at the 61st American…
For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the 61st American Society of Hematology (ASH) Annual Meeting. By analyzing AML tissue samples from…
A woman worried about heart disease might check the amount of saturated fats in her snack food. A man with diabetes might track the carbohydrates in his lunch. We know our diet can seriously affect our health. So why don’t we study it as thoroughly as we study our genetics? The United States Department of Agriculture tracks roughly 150 fats,…
“Proteins are the workers in the cell, and it’s important to know their shape,” says Chris Sander, PhD, director of Dana-Farber’s cBio Center in the Department of Data Sciences. Sander and his colleagues have now demonstrated a powerful “experimental evolution” method to discover details of protein shape and function, and the method may find uses across a very broad spectrum of…
A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma, easing concerns that these patients are at heightened risk for severe immune-related complications. The study, to be presented today at the 61st American Society of Hematology (ASH) Annual Meeting by Reid Merryman, MD, attending physician…